In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients..
with ART. In the past twenty years, a large set of clinical trials demonstrated that intermittent interleukin (IL)-2 therapy increased the CD4 T-cell pool in HIV-infected patients and induced, in a large majority of patients, significant and sustained increases in CD4 T-cell count beyond that seen in patients treated with antiviral drugs alone. In particular, recombinant IL-2 therapy raised naive and central memory CD4 + cells expressing CD25, the alpha chain of the IL-2 receptor, greater than antiretroviral drugs alone (1) (2) (3) (4) (5) (6) . This population accounted for up to 70% of the total CD4 + T cell pool of IL-2-treated patients and persisted for a long time.
The clinical impact of IL-2 was evaluated in two long-run large phase III trials (SILCAAT and ESPRIT) involving almost 6000 chronically HIV-1 infected patients. Results recently reported showed that, despite a sustained increase in CD4 + T cell counts, over a median follow up of 7-8 years, IL-2 treated patients did not experience a better clinical outcome (7).
These disappointing results have remained unexplained so far. In mice, IL-2 has been shown to be essential for the maintenance and function of a regulatory T cell subset characterized by the expression of CD25 and of the transcription factor FOXP3 (CD4   +   CD25 hi FOXP3 + T cells, Treg) (8) . Neutralization of IL-2 resulted in a decrease in peripheral Treg and the development of autoimmune pathologies (9) . Furthermore, analysis of IL-2 or CD25-deficient mice revealed that IL-2 signalling was essential for peripheral maintenance and function of Treg, but not for their generation in the thymus (10, 11 (Fig. 3a) . (Fig. 4) . Analysis of the gene expression signature after three IL-2 treatment cycles at week 24 revealed that of the 60 genes differentially expressed at this time point (P<0.001), 50 were also differentially expressed at week 0 (Fig. 4 and Supplementary Table  3) . We noted, however, also several differences between CD4 + CD25 + T cells before IL-2 treatment and CD4 + CD25 + T cells after IL-2 treatment. The chemokine receptor CCR8 (27) was expressed at lower levels after 3 treatment cycles, whereas the dual-specificity phosphatase 6 (DUSP6), a negative regulator of ERK2 activity involved in tuning T cell excitation thresholds ( (Fig. 6) . (32) . Moreover, analysis of T cell cycling using Ki-67 staining showed that these cells exhibit a low rate of turn over even in HIV untreated patients, which is in sharp contrast with the behaviour of conventional T cells (15) . Together, these observations remind characteristics of Treg and strengthen our findings that IL-2 administration leads to expansion 
Materials and methods
A detailed description of procedures is given in the supplementary methods section. Patients. 31 HIV-infected patients who had received, while on antiretroviral therapy, at least 3 cycles of IL-2 in the frame of ANRS trials or expanded open access to IL-2 were included in the study. Blood samples collected on EDTA tubes were processed within 3 hours. The clinical characteristics of the patients are depicted in Supplementary Table 1 . Median (ranges) CD4 T-cell counts were 445/µl (95-919) prior to IL-2 treatment and 843/µl (422-2348), at the time of sampling. All patients but three had plasma HIV-RNA levels below 50 copies/ml. Patients had received a median (ranges) of 7 (3-18) IL-2 cycles. The median time between testing and the last IL-2 cycle was 2 months (ranges: 2-59). Written informed consent was obtained from all the patients, according to human experimentation guidelines from national ethical committees. Cell Isolation. CD4 + T lymphocytes were purified from peripheral blood as previously described (22, (35) (36) (37) . Flow Cytometric Analysis. Phenotyping of cell subsets was performed on fresh PBMC by four-colour flow cytometry using the mAbs listed in the supplementary methods section. Analyses were performed using FACScalibur™ or LSRII cytometer and CellQuest™ software (Becton Dickinson, San Jose, California, USA) on at least 1000 events. Gating was restricted to the population of lymphocytes according to their light scattering properties. T cells from HIV patients and healthy donors was performed using Applied Biosystems 1700 microarray platform following protocols provided by the supplier as previously described (38) . Microarray data were deposited in the MACE database (http://mace.ihes.fr/) with the accession numbers 2560865806 (data from HIV patients) and 2828616462 (healthy donors). Statistical analyses. Data are expressed as mean ± SEM for percentages and median and ranges for absolute values. Statistical comparisons were performed using two-tailed unpaired non parametric Mann Whitney test for comparisons between groups (IL-2 vs controls) and
Wilcoxon rank test for comparisons between CD4 cell subsets. Significance was considered for P #0.05. T cells were cultured for 5 days with 5µg/ml purified tuberculin (PPD), 5µg/ml p24, 
